{
    "clinical_study": {
        "@rank": "114368", 
        "acronym": "ACHTAR", 
        "arm_group": {
            "arm_group_label": "-ACHTHAR", 
            "arm_group_type": "Experimental", 
            "description": "Subcutaneous ACTHAR 5 days of 80 IU and 10 Days of 40 IU"
        }, 
        "brief_summary": {
            "textblock": "The goal of the study is to determine the earliest structural changes in the optic nerve\n      during the acute event and during the twelve months of recovery following Acthar treatment."
        }, 
        "brief_title": "Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Optic Neuritis", 
        "condition_browse": {
            "mesh_term": [
                "Neuritis", 
                "Optic Neuritis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  unilateral acute demyelinating optic neuritis\n\n          -  Able to provide informed consent\n\n          -  age 18 or older\n\n          -  can perform the above listed electrophysiologic diagnostic testing\n\n          -  can perform high and low contrast visual acuity and visual field perimetry\n\n        Exclusion Criteria:\n\n          -  prior diagnosis of remitting/relapsing multiple sclerosis(RRMS)\n\n          -  secondary progressive MS(SPMS)\n\n          -  primary progressive MS (PPMS)\n\n          -  undergoing treatment with medications approve for treatment of RRMS(except\n             corticosteroids for a condition not involving central nervous system demyelination)\n\n          -  prior diagnosis of systemic lupus erythematosis\n\n          -  mixed connective tissue disease\n\n          -  vasculitis\n\n          -  sarcoidosis\n\n          -  neuro-myelitis optica"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987167", 
            "org_study_id": "13-330", 
            "secondary_id": "ACTHAR"
        }, 
        "intervention": {
            "arm_group_label": "-ACHTHAR", 
            "description": "Injectable Gel", 
            "intervention_name": "ACTHAR", 
            "intervention_type": "Drug", 
            "other_name": "Repository Corticotropin"
        }, 
        "intervention_browse": {
            "mesh_term": "Adrenocorticotropic Hormone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "acute optic neuritis", 
        "lastchanged_date": "November 12, 2013", 
        "location": {
            "contact": {
                "email": "mmassini@willseye.org", 
                "last_name": "Maria C Massini, COT", 
                "phone": "215-825-4725"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19145"
                }, 
                "name": "Neuro Ophthalmologic Associates"
            }, 
            "investigator": [
                {
                    "last_name": "Robert C Sergott, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Mark L Moster, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Esther Bisker, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Tim Kim, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Potential Neuroprotection With ACTHAR Following Acute Optic Neuritis", 
        "other_outcome": [
            {
                "description": "To define the electrophysiological changes at the onset and following an acute event of optic neuritis with Multifocal electroretinography(mERG) and visual evoked potentials (VEP)", 
                "measure": "Preservation and/or restoration of electrophysiological parameters for patients with acute optic neuritis.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "to determine the earliest structural, physiological, and metabolic changes in the optic nerve during an acute event of demyelinating optic neuritis and the natural history of these changes over 6 months.", 
                "measure": "Structual, Physiological and Metabolic changes during an acute event of optic neuritis", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "overall_official": {
            "last_name": "Robert C Sergott, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Data and Safety Monitoring Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Functional with low contrast visual acuity in bothe the eye acutely affected by optic neuritis and the clinically unaffected eye.", 
            "measure": "Neuro-protection", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987167"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To define the objective (micron thickness, volumetric analysis) and subjective (histopathological changes) of spectral domain optical coherence tomography (SD-OCT) at the time of clinical presentation of acute optic neuritis and during 6 months of recovery following ACTHAR treatment.", 
            "measure": "Preservation of retinal nerve fiber layer.", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Neuro-Ophthalmologic Associates, PC", 
        "sponsors": {
            "collaborator": {
                "agency": "Questcor Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Neuro-Ophthalmologic Associates, PC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}